Leading the way to safer medication
 Crosscheck  Recommender

Anakinra

Therapeutic Indications

Anakinra is indicated for:

Still's Disease

Irrespective of gender only Adults (18 years old or older)

Anakinra is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Subcutaneous - 1-4 mg/kg once a day

Rheumatoid arthritis (RA)

Irrespective of gender only Adults (18 years old or older)

Anakinra is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Subcutaneous - 100 mg once a day

Cryopyrin-Associated Periodic Syndromes (CAPS)

Irrespective of gender only Infants (40 days - 1 year old) , Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

Anakinra is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of CAPS, including:

  • Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)
  • Muckle-Wells Syndrome (MWS)
  • Familial Cold Autoinflammatory Syndrome (FCAS)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Subcutaneous - 1-8 mg/kg once a day

Contraindications

Active ingredient Anakinra is contraindicated in the following cases:

Neutropenia

No gender/age discrimination

Anakinra was commonly associated with neutropenia (ANC <1.5 × 109/l) in placebo-controlled studies in RA and cases of neutropenia have been observed in patients with CAPS and Still’s disease.

Anakinra treatment should not be initiated in patients with neutropenia (ANC <1.5 × 109/l). It is recommended that neutrophil counts be assessed prior to initiating anakinra treatment, and while receiving anakinra, monthly during the first 6 months of treatment and quarterly hereafter. In patients who become neutropenic (ANC <1.5 × 109/l) the ANC should be monitored closely and anakinra treatment should be discontinued. The safety and efficacy of anakinra in patients with neutropenia have not been evaluated.